Trial · NCT03317002

AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).

NCT03317002, Phase 2, Completed, AstraZeneca; results first posted 2021-06-30

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD). Trials, record NCT03317002. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03317002

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).
NCT number: NCT03317002
Status: Completed
Phases: Phase 2
Enrollment: 129 participants, actual
Lead sponsor: AstraZeneca
Conditions: Coronary Artery Disease
Interventions: AZD5718, AZD5718, Placebo
First posted: 2017-10-23
Last updated: 2021-06-30
Results first posted: 2021-06-30

Source ClinicalTrials.gov

Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change From Baseline in Creatinine-normalized u-LTE4 at Week 4	Baseline and 4 weeks	Creatinine-normalized u-LTE4 is calculated as uLTE4/creatinine
Secondary	Change From Baseline in Creatinine-normalized u-LTE4 at Week 12	Baseline and 12 weeks	Creatinine-normalized u-LTE4 is calculated as uLTE4/creatinine
Secondary	Change From Baseline in CFVR at Week 12	Baseline and 12 weeks	CFVR = Coronary Flow Velocity Reserve = LAD(hyperaemic)/LAD(rest)
Secondary	Change From Baseline in CFVR at Week 4	Baseline and 4 weeks	CFVR = Coronary Flow Velocity Reserve = LAD(hyperaemic)/LAD(rest)
Secondary	Summary of Plasma Concentrations of AZD5718	16 weeks
Secondary	Change From Baseline in LAD Hypereamic Flow at 4 Weeks	Baseline and 4 weeks	LAD=Left Anterior Descending
Secondary	Change From Baseline in LVEF at 4 Weeks	Baseline and 4 weeks	LVEF=Left Ventricular Ejection Fraction
Secondary	Change From Baseline in LV Longitudinal Early Diastolic Strain Rate at 4 Weeks	Baseline and 4 weeks	LV=Left Ventricular
Secondary	Change From Baseline in LV-GLS at Rest at Week 4	Baseline and 4 weeks	LV-GLS = Left Ventricular Global Longitudinal Strain
Secondary	Change From Baseline in LV-GCS at Rest at Week 4	Baseline and 4 weeks	LV-GCS = Left Ventricular Global Circumferential Strain

1 to 10 of 11Source ClinicalTrials.gov

See all 11 registered outcomes

Outcomes11

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change From Baseline in Creatinine-normalized u-LTE4 at Week 4	Baseline and 4 weeks	Number of participants analysed differs from participant flow module due to missing data	Ratio	GEOMETRIC_MEAN
SECONDARY	Change From Baseline in Creatinine-normalized u-LTE4 at Week 12	Baseline and 12 weeks	Number of participants analysed differs from participant flow module due to missing data	Ratio	GEOMETRIC_MEAN
SECONDARY	Change From Baseline in CFVR at Week 12	Baseline and 12 weeks	Number of participants analysed differs from participant flow module due to missing data	Ratio	GEOMETRIC_MEAN
SECONDARY	Change From Baseline in CFVR at Week 4	Baseline and 4 weeks	Number of participants analysed differs from participant flow module due to missing data	Ratio	GEOMETRIC_MEAN
SECONDARY	Summary of Plasma Concentrations of AZD5718	16 weeks	Number of participants analysed differs from participant flow module due to missing data	nmol/L	GEOMETRIC_MEAN
SECONDARY	Change From Baseline in LAD Hypereamic Flow at 4 Weeks	Baseline and 4 weeks	Number of participants analysed differs from participant flow module due to missing data	m/sec	MEAN
SECONDARY	Change From Baseline in LVEF at 4 Weeks	Baseline and 4 weeks	Number of participants analysed differs from participant flow module due to missing data	percent LVEF	MEAN
SECONDARY	Change From Baseline in LV Longitudinal Early Diastolic Strain Rate at 4 Weeks	Baseline and 4 weeks	Number of participants analysed differs from participant flow module due to missing data	1/s	GEOMETRIC_MEAN
SECONDARY	Change From Baseline in LV-GLS at Rest at Week 4	Baseline and 4 weeks	Number of participants analysed differs from participant flow module due to missing data	Percent LV-GLS	MEAN
SECONDARY	Change From Baseline in LV-GCS at Rest at Week 4	Baseline and 4 weeks	Number of participants analysed differs from participant flow module due to missing data	Percent	MEAN

1 to 10 of 11Source ClinicalTrials.gov

See all 11 outcomes

Results by group46

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change From Baseline in Creatinine-normalized u-LTE4 at Week 4	AZD5718 (200 mg)	0.04	Geometric Coefficient of Variation 92.55	Ratio
Change From Baseline in Creatinine-normalized u-LTE4 at Week 4	AZD5718 (50 mg)	0.09	Geometric Coefficient of Variation 84.32	Ratio
Change From Baseline in Creatinine-normalized u-LTE4 at Week 4	Placebo	1.09	Geometric Coefficient of Variation 44.38	Ratio
Change From Baseline in Creatinine-normalized u-LTE4 at Week 12	AZD5718 (200 mg)	0.04	Geometric Coefficient of Variation 92.55	Ratio
Change From Baseline in Creatinine-normalized u-LTE4 at Week 12	AZD5718 (50 mg)	0.09	Geometric Coefficient of Variation 84.32	Ratio
Change From Baseline in Creatinine-normalized u-LTE4 at Week 12	Placebo	1.09	Geometric Coefficient of Variation 44.38	Ratio
Change From Baseline in CFVR at Week 12	AZD5718 (200 mg)	0.93	Geometric Coefficient of Variation 23.64	Ratio
Change From Baseline in CFVR at Week 12	AZD5718 (50 mg)	0.98	Geometric Coefficient of Variation 39.53	Ratio
Change From Baseline in CFVR at Week 12	Placebo	1.16	Geometric Coefficient of Variation 33.46	Ratio
Change From Baseline in CFVR at Week 4	AZD5718 (200 mg)	1.03	Geometric Coefficient of Variation 28.34	Ratio

1 to 10 of 46Source ClinicalTrials.gov

See all 46 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	AZD5718 (200 mg)	52
Overall Study	STARTED	AZD5718 (50 mg)	25
Overall Study	STARTED	Placebo	52
Overall Study	COMPLETED	AZD5718 (200 mg)	50
Overall Study	COMPLETED	AZD5718 (50 mg)	24
Overall Study	COMPLETED	Placebo	51
Overall Study	NOT COMPLETED	AZD5718 (200 mg)	2
Overall Study	NOT COMPLETED	AZD5718 (50 mg)	1
Overall Study	NOT COMPLETED	Placebo	1

Source ClinicalTrials.gov

Adverse events75

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Nasopharyngitis	Infections and infestations	AZD5718 (200 mg)	6	52
other	Nasopharyngitis	Infections and infestations	AZD5718 (50 mg)	4	25
other	Nasopharyngitis	Infections and infestations	Placebo	7	51
other	Anaemia	Blood and lymphatic system disorders	AZD5718 (200 mg)	4	52
other	Anaemia	Blood and lymphatic system disorders	AZD5718 (50 mg)	0	25
other	Anaemia	Blood and lymphatic system disorders	Placebo	2	51
other	Dyspnoea	Respiratory, thoracic and mediastinal disorders	AZD5718 (200 mg)	6	52
other	Dyspnoea	Respiratory, thoracic and mediastinal disorders	AZD5718 (50 mg)	4	25
other	Dyspnoea	Respiratory, thoracic and mediastinal disorders	Placebo	7	51
other	Cough	Respiratory, thoracic and mediastinal disorders	AZD5718 (200 mg)	5	52

1 to 10 of 75Source ClinicalTrials.gov

See all 75 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	AZD5718 (200 mg)	0	52
Total, all-cause mortality	AZD5718 (50 mg)	0	25
Total, all-cause mortality	Placebo	0	51
Total, other adverse events	AZD5718 (200 mg)	27	52
Total, other adverse events	AZD5718 (50 mg)	12	25
Total, other adverse events	Placebo	22	51
Total, serious adverse events	AZD5718 (200 mg)	4	52
Total, serious adverse events	AZD5718 (50 mg)	3	25
Total, serious adverse events	Placebo	4	51

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
35842004	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03317002

GET https://conductscience.org/api/trials/v1/NCT03317002/results?page=2

API reference For AI assistants